Literature DB >> 2037601

Structure-activity relationship study of human interleukin-3. Identification of residues required for biological activity by site-directed mutagenesis.

N A Lokker1, N R Movva, U Strittmatter, B Fagg, G Zenke.   

Abstract

Recombinant human interleukin-3 (rhuIL-3) variants were generated by site-directed mutagenesis and expression in Escherichia coli. Amino acid deletions and substitutions were made in the previously identified epitopes of two huIL-3-specific neutralizing monoclonal antibodies (mAbs). The rhuIL-3 variants were analyzed for their ability to bind to the IL-3 receptor and to induce the proliferation of the human IL-3-dependent cell line M-O7. Several deletion mutants spanning the epitopes of these neutralizing mAbs indicated the importance of residues Pro33 and Leu34 for biological activity. Further, substitution of Pro33 with Asn (Asn33) showed an enhanced proliferative activity (4-fold) and a moderate increase in receptor binding (2-fold) compared to wild-type (wt) rhuIL-3. The most remarkable change, however, was seen with variant Gly33, which showed a 14-fold increase in promoting the growth of M-O7 cells without a significant modification in its receptor binding capacity. In contrast, substitution of Leu34 with Gly (Gly34) yielded an IL-3 variant that had a 25-fold decreased receptor binding capacity and proliferative activity, while Glu34 had properties similar to wild-type rhuIL-3. Analysis of the binding of these variants to different rhuIL-3-specific monoclonal antibodies suggested that no major modification had occurred in their conformations. These results indicate that both residues, Pro33 and Leu34, play a critical role in modulating the activity of rhuIL-3.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037601

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Structure-function studies of human ciliary neurotrophic factor.

Authors:  A Negro; V Corsa; G Corona; C Grandi; S D Skaper; L Callegaro
Journal:  Neurochem Res       Date:  1994-02       Impact factor: 3.996

2.  Molecular evolution of interleukin-3.

Authors:  H Burger; G Wagemaker; J A Leunissen; L C Dorssers
Journal:  J Mol Evol       Date:  1994-09       Impact factor: 2.395

3.  A human interleukin 3 analog with increased biological and binding activities.

Authors:  A F Lopez; M F Shannon; S Barry; J A Phillips; B Cambareri; M Dottore; P Simmons; M A Vadas
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

4.  Inter-species chimeras of leukaemia inhibitory factor define a major human receptor-binding determinant.

Authors:  C M Owczarek; M J Layton; D Metcalf; P Lock; T A Willson; N M Gough; N A Nicola
Journal:  EMBO J       Date:  1993-09       Impact factor: 11.598

5.  A cytokine-cytokine interaction in the assembly of higher-order structure and activation of the interleukine-3:receptor complex.

Authors:  Raja Dey; Kunmei Ji; Zhigang Liu; Lin Chen
Journal:  PLoS One       Date:  2009-04-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.